<?xml version="1.0" encoding="UTF-8"?><feed xmlns="http://www.w3.org/2005/Atom">
  <title>研发客 | wechat-feeds</title>
  <id>https://github.com/hellodword/wechat-feeds</id>
  <updated>2021-01-20T07:53:24+08:00</updated>
  <subtitle>《研发客》公众号由上海汐潮信息技术有限公司提供，行业资深中英文独立编辑记者创办。我们观察药物创新生态，报道临床研究与监管科学。</subtitle>
  <link href="https://github.com/hellodword/wechat-feeds"></link>
  <author>
    <name>hellodword</name>
  </author>
  <entry>
    <title>在日本，患者可以参与策划新药研发｜第一现场</title>
    <updated>2021-01-19T23:17:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/UIH0joq9bzRldR9qzdIbsQ</id>
    <link href="https://mp.weixin.qq.com/s/UIH0joq9bzRldR9qzdIbsQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>重点关注细胞和基因疗法   拜耳以创新突破引领医疗转型 | 新闻稿</title>
    <updated>2021-01-19T23:17:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/qSctkzhchT2TW1HzXM0vkg</id>
    <link href="https://mp.weixin.qq.com/s/qSctkzhchT2TW1HzXM0vkg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>丽珠：从传统迈向创新｜大话JPM</title>
    <updated>2021-01-19T23:17:10+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-19:/s/8t68wHAW-oVr_RKDjo6WfA</id>
    <link href="https://mp.weixin.qq.com/s/8t68wHAW-oVr_RKDjo6WfA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>国内首个！博雅辑因CRISPR/Cas 9基因编辑治疗β地中海贫血产品ET-01进入临床试验｜新闻稿</title>
    <updated>2021-01-18T23:06:50+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-18:/s/BgK4tSxpCIn3Eq1p1zVbKw</id>
    <link href="https://mp.weixin.qq.com/s/BgK4tSxpCIn3Eq1p1zVbKw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>中国CRO锐得麦携手创新药企迈入全球临床2.0时代 | 江湖</title>
    <updated>2021-01-17T21:55:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/FwjUlmGOh0gG2a7O-o-Q2w</id>
    <link href="https://mp.weixin.qq.com/s/FwjUlmGOh0gG2a7O-o-Q2w" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>万春：普那布林多项联合用药数据亮眼 | 大话JPM</title>
    <updated>2021-01-17T21:55:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/85wJ1hh7JPIYZdtRU4uiKQ</id>
    <link href="https://mp.weixin.qq.com/s/85wJ1hh7JPIYZdtRU4uiKQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>康希诺：新型脑膜炎疫苗接近上市 | 大话JPM</title>
    <updated>2021-01-17T21:55:18+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/OzdDZrEKGksJOUMoUWNxPA</id>
    <link href="https://mp.weixin.qq.com/s/OzdDZrEKGksJOUMoUWNxPA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>百济神州：或将公布泽布替尼治疗CLL头对头数据｜大话JPM</title>
    <updated>2021-01-17T09:10:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/wpPZblLuOFVHGfiOyuLkOA</id>
    <link href="https://mp.weixin.qq.com/s/wpPZblLuOFVHGfiOyuLkOA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>荣昌生物：预测泰它西普一季度获批上市｜大话JPM</title>
    <updated>2021-01-17T09:10:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/hGKl6_9NfE1AI9Y2OjzAiw</id>
    <link href="https://mp.weixin.qq.com/s/hGKl6_9NfE1AI9Y2OjzAiw" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>中生制药：安罗替尼获批MTC第四适应症 | 大话JPM</title>
    <updated>2021-01-17T09:10:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/MXI7CYA8otmtKF293gtm1g</id>
    <link href="https://mp.weixin.qq.com/s/MXI7CYA8otmtKF293gtm1g" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>岸迈：与强生竞争EGFR/MET 双抗 | 大话JPM</title>
    <updated>2021-01-17T09:10:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/KXrOqzttlshS1YSfhZ2pIA</id>
    <link href="https://mp.weixin.qq.com/s/KXrOqzttlshS1YSfhZ2pIA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>和誉：自建一体化靶点和药物发现平台 | 大话JPM</title>
    <updated>2021-01-17T09:10:05+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-17:/s/8g_QLA4RDPyNKwe6-OydfA</id>
    <link href="https://mp.weixin.qq.com/s/8g_QLA4RDPyNKwe6-OydfA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>传奇：Cilta-cel疗法总缓解率96.9% | 大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/z1jo4DA4yZ8M1XLpmckgvA</id>
    <link href="https://mp.weixin.qq.com/s/z1jo4DA4yZ8M1XLpmckgvA" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>康方：超越联合疗法的双IO靶点双抗｜大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/LY9VxIHG3XDcGG3FJx-lfg</id>
    <link href="https://mp.weixin.qq.com/s/LY9VxIHG3XDcGG3FJx-lfg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>科望：一年一分子｜大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/u_keaC8RnsOXR4z87p0nkQ</id>
    <link href="https://mp.weixin.qq.com/s/u_keaC8RnsOXR4z87p0nkQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>智飞：结核领域有所斩获｜大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/RS6JFz1o8Xg9jsG_ZbqGEQ</id>
    <link href="https://mp.weixin.qq.com/s/RS6JFz1o8Xg9jsG_ZbqGEQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>嘉和：CDK4/6抑制剂可能同类最优 | 大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/4A8lBMw0ucHmXb0wOl0d1Q</id>
    <link href="https://mp.weixin.qq.com/s/4A8lBMw0ucHmXb0wOl0d1Q" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>再鼎：合作项目着眼全球未满足临床需求 | 大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/jvK3aSbP31ifB98P4FUMFQ</id>
    <link href="https://mp.weixin.qq.com/s/jvK3aSbP31ifB98P4FUMFQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>信达：信迪利今年在美递交BLA | 大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/at4pdEsWGJQvlI70lofdnQ</id>
    <link href="https://mp.weixin.qq.com/s/at4pdEsWGJQvlI70lofdnQ" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
  <entry>
    <title>君实：特瑞普利单抗有望成为最快在美上市的国产PD-1｜大话JPM</title>
    <updated>2021-01-16T10:47:43+08:00</updated>
    <id>tag:mp.weixin.qq.com,2021-01-16:/s/Im03yAHG7nYJ5yFgNFKZxg</id>
    <link href="https://mp.weixin.qq.com/s/Im03yAHG7nYJ5yFgNFKZxg" rel="alternate"></link>
    <summary type="html"></summary>
  </entry>
</feed>